Alzheimer’s Disease Determination by a Dual Probe on Gold Nanourchins and Nanohorn Hybrids
Authors Qiu Z, Shen Q, Jiang C, Yao L, Sun X, Li J, Duan C, Li R, Li X, Gopinath SCB, Anbu P, Lakshmipriya T, Li X
Received 19 January 2021
Accepted for publication 1 March 2021
Published 19 March 2021 Volume 2021:16 Pages 2311—2322
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Israel (Rudi) Rubinstein
Zhengguo Qiu,1 Qianhe Shen,2 Chao Jiang,3 Li Yao,4 Xiaopeng Sun,5 Jing Li,6 Chongzhen Duan,1 Rui Li,1 Xiuli Li,1 Subash CB Gopinath,7,8 Periasamy Anbu,9 Thangavel Lakshmipriya,8 Xu Li10
1Department of Anesthesiology, Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi, 712000, People’s Republic of China; 2Department of Anesthesiology, Xi’an GemFlower Changqing Hospital, Xi’an, Shaanxi, 710200, People’s Republic of China; 3The Third Department of Neurology, The Second Affiliated Hospital of Xi’an Medical University, Xi’an, Shaanxi, 710038, People’s Republic of China; 4Department of Neurology, The Hospital of Xidian Group, Xi’an, Shaanxi, 710077, People’s Republic of China; 5Department of Otolaryngology, The Second Affiliated Hospital of Xi’an Medical University, Xi’an, Shaanxi, 710038, People’s Republic of China; 6Department of Anesthesiology, The Second Affiliated Hospital of Xi’an Medical University, Xi’an, Shaanxi, 710038, People’s Republic of China; 7Faculty of Chemical Engineering Technology, Universiti Malaysia Perlis (UniMAP), Arau, Perlis, 02600, Malaysia; 8Institute of Nano Electronic Engineering, Universiti Malaysia Perlis (UniMAP), Kangar, 01000, Malaysia; 9Department of Biological Engineering, College of Engineering, Inha University, Incheon, 402-751, Republic of Korea; 10Department of Surgery and Anesthesiology, Xi’an Hospital of Traditional Chinese Medicine, Xi’an, Shaanxi, People’s Republic of China
Correspondence: Xu Li Email [email protected]
Background: Alzheimer’s disease (AD) is a neurodegenerative chronic disorder that causes dementia and problems in thinking, cognitive impairment and behavioral changes. Amyloid-beta (Aβ) is a peptide involved in AD progression, and a high level of Aβ is highly correlated with severe AD. Identifying and quantifying Aβ levels helps in the early treatment of AD and reduces the factors associated with AD.
Materials and Methods: This research introduced a dual probe detection system involving aptamers and antibodies to identify Aβ. Aptamers and antibodies were attached to the gold (Au) urchin and hybrid on the carbon nanohorn-modified surface. The nanohorn was immobilized on the sensor surface by using an amine linker, and then a Au urchin dual probe was immobilized.
Results: This dual probe-modified surface enhanced the current flow during Aβ detection compared with the surface with antibody as the probe. This dual probe interacted with higher numbers of Aβ peptides and reached the detection limit at 10 fM with R2=0.992. Furthermore, control experiments with nonimmune antibodies, complementary aptamer sequences and control proteins did not display the current responses, indicating the specific detection of Aβ.
Conclusion: Aβ-spiked artificial cerebrospinal fluid showed a similar response to current changes, confirming the selective identification of Aβ.
Keywords: amyloid-beta, biomarker, nanomaterial, aptamer, antibody
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]